On the other hand, the multifaceted effects of HDAC (Histone Deacetylase) inhibitors on cancer cells make them potential candidates for therapeutic interventions in hematological malignancies and CTCL. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.